Breast Cancer
J6M-MC-JSGD A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2).
- Details
ClinicalTrials.gov ID:
NCT07174336
Diagnosis Type:
NA
USOR Number:
- Address
,
P: